본문으로 건너뛰기
← 뒤로

The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.

Cell death & disease 2026

Searle J, Menotti M, McDaid WJ, Baker MJ, Chaturvedi A, Ginn L, Reed H, Carter M, Blackhall F, Lindsay CR, Malliri A

📝 환자 설명용 한 줄

The E3 ubiquitin ligase HUWE1 modifies a diverse network of substrate proteins by ubiquitination, through which it regulates various intracellular processes and contributes to both oncogenic and tumou

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Searle J, Menotti M, et al. (2026). The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.. Cell death & disease. https://doi.org/10.1038/s41419-026-08672-7
MLA Searle J, et al.. "The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.." Cell death & disease, 2026.
PMID 41942468

Abstract

The E3 ubiquitin ligase HUWE1 modifies a diverse network of substrate proteins by ubiquitination, through which it regulates various intracellular processes and contributes to both oncogenic and tumour suppressor mechanisms in different cancer contexts. Here, by analysing human lung adenocarcinoma (LUAD) patient samples, we reveal that HUWE1 protein expression is commonly upregulated in LUAD tumours compared to normal adjacent lung tissue and that this increase is associated with tumour stage. Using multiple, independent murine models of LUAD initiation and growth, we identify that Huwe1 is essential for mutant Kras-induced lung tumour development and reveal a novel, p53-independent requirement for Huwe1 in LUAD. Mechanistically, we demonstrate induction of senescence following HUWE1 depletion - characterised by impaired proliferation, an atypical cell cycle distribution, emergence of morphologically abnormal enlarged cells, increased β-galactosidase activity, and transcriptional reprogramming associated with inflammatory senescence-associated secretory phenotype (SASP) signalling and NFκB activation. Together, these data highlight a crucial role for HUWE1 in mutant Kras-induced LUAD tumorigenesis and in the continued growth and proliferation of established LUAD cells, confirming HUWE1 as a rational therapeutic target for LUAD.